The detection of CD40 expression in tumor cells needs to be addressed for this targetable molecule to be effectively implemented in cancer therapeutics, with the goal of informing the development of less toxic, yet more potent, future pharmaceuticals and optimizing patient selection in future clinical trials. Here, CD40 is linked to neoplasm.